{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.013, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.01, "sharesOutstanding": 54000000, "bookValue": 0.026, "fiftyDayAverage": 0.01876, "fiftyDayAverageChange": -0.005759999, "fiftyDayAverageChangePercent": -0.30703622, "twoHundredDayAverage": 0.02976, "twoHundredDayAverageChange": -0.01676, "twoHundredDayAverageChangePercent": -0.56317204, "marketCap": 1046436, "priceToBook": 0.5, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1600063200000, "priceHint": 4, "marketState": "REGULAR", "exchange": "FRA", "shortName": "WAVERLEY PHARMA INC.", "longName": "Waverley Pharma Inc.", "messageBoardId": "finmb_533780351", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": 0.0, "regularMarketTime": 1683875701, "regularMarketDayHigh": 0.013, "regularMarketDayRange": "0.013 - 0.013", "regularMarketDayLow": 0.013, "regularMarketVolume": 3000, "regularMarketPreviousClose": 0.013, "bid": 0.013, "ask": 0.027, "fullExchangeName": "Frankfurt", "financialCurrency": "CAD", "regularMarketOpen": 0.013, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.0020000003, "fiftyTwoWeekLowChangePercent": 0.18181822, "fiftyTwoWeekRange": "0.011 - 0.069", "fiftyTwoWeekHighChange": -0.055999998, "fiftyTwoWeekHighChangePercent": -0.8115942, "fiftyTwoWeekLow": 0.011, "fiftyTwoWeekHigh": 0.069, "symbol": "5GZ.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "4-1250 Waverley Street", "city": "Winnipeg", "state": "MB", "zip": "R3T 6C6", "country": "Canada", "website": "https://www.waverleypharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes cancer therapeutics in the United Kingdom, European Union, and North America. It focuses on the generic oncology injectable products. The company sells generic oncology products comprising capecitabine, temozolomide, and erlotinib. Its products under development include injectable generic chemotherapy drugs, such as Pemetrexed for the treatment of non-small cell lung cancer and pleural mesothelioma; and Bortezomib to treat multiple myeloma and mantle cell lymphoma. The company has a collaboration agreement with the University of Manitoba for the development of a synthetic library of chloroquine analogs to treat COVID-19. Waverley Pharma Inc. is headquartered in Winnipeg, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Larry  Thiessen", "title": "Pres & CEO", "fiscalYear": 2021, "totalPay": {"raw": 33648, "fmt": "33.65k", "longFmt": "33,648"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Haaris  Uddin B.Com., CPA", "title": "Chief Financial Officer", "fiscalYear": 2021, "totalPay": {"raw": 82252, "fmt": "82.25k", "longFmt": "82,252"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}